Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

544
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
544
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

426
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
426
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

245
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
245
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

346
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
346
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

701
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
701
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

278
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).

Respiratory research·2026
Same author

Lung disease in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026
Same author

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Unravelling viral identity: avoiding the trap of endogenous sequences for viral surveillance of small ruminant oncogenic retroviruses.

Virus evolution·2026
Same author

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

The New England journal of medicine·2026

Related Experiment Video

Updated: Oct 25, 2025

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.5K

Tuberous sclerosis complex for the pulmonologist.

Yasmine Rebaine1,2,3,4, Mouhamad Nasser1,4, Barbara Girerd5,6,7

  • 1Dept of Respiratory Medicine, National Reference Coordinating Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France.

European Respiratory Review : an Official Journal of the European Respiratory Society
|August 5, 2021
PubMed
Summary
This summary is machine-generated.

Tuberous sclerosis complex (TSC) is a rare genetic disorder causing lung issues like lymphangioleiomyomatosis (LAM). mTOR inhibitors are key treatments for LAM, while multifocal micronodular pneumocyte hyperplasia (MMPH) typically requires no intervention.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.9K

Related Experiment Videos

Last Updated: Oct 25, 2025

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.5K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.9K

Area of Science:

  • Genetics
  • Pulmonology
  • Oncology

Background:

  • Tuberous sclerosis complex (TSC) is a rare, autosomal-dominant genetic disorder caused by mutations in TSC1 or TSC2 genes.
  • It leads to mammalian target of rapamycin (mTOR) hyperactivation, affecting multiple organs.
  • Pulmonary manifestations include lymphangioleiomyomatosis (LAM), multifocal micronodular pneumocyte hyperplasia (MMPH), and chylous effusions.

Purpose of the Study:

  • To review the pulmonary manifestations of Tuberous Sclerosis Complex (TSC).
  • To describe the characteristics and management of LAM and MMPH in TSC patients.
  • To highlight the role of mTOR inhibitors in treating LAM.

Main Methods:

  • Review of existing literature on TSC and its pulmonary complications.
  • Analysis of clinical presentation and imaging findings (CT scans) for LAM and MMPH.
  • Discussion of current treatment strategies, focusing on mTOR inhibitors.

Main Results:

  • LAM, a cystic lung disease, occurs in 30-40% of adult females with TSC and can affect males (TSC-LAM).
  • TSC-LAM is generally milder than sporadic LAM (S-LAM) and presents as diffuse, thin-walled cysts.
  • LAM complications include spontaneous pneumothoraces (up to 70% of patients) with high recurrence.
  • MMPH presents as nodules on HRCT and is typically benign, requiring no treatment.

Conclusions:

  • TSC involves significant pulmonary risks, primarily LAM and MMPH.
  • Early diagnosis and management of LAM, particularly with mTOR inhibitors, are crucial.
  • Understanding these manifestations aids in patient care and prognosis for TSC patients.